Supplementary Materials

The PDF file includes:

  • Fig. S1. Overview of the workflow for the LRRK2 Safety Initiative.
  • Fig. S2. Rab10 protein phosphorylation in lung (Phos-tag gels).
  • Fig. S3. Design of lung function tests.
  • Table S1. Macroscopic and microscopic analysis of macaque brain, lung, and kidney.
  • Table S2. Unbound and total plasma/tissue concentrations of LRRK2 inhibitors after 15 days of treatment.
  • Table S3. Microscopic lung observations after lung function tests.
  • Table S4. Schedule for dosing, monitoring, necropsy, and tissue collection.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Western blotting of pS935-LRRK2 and total LRRK2 in macaque lung, PBMCs, and brain.
  • Data file S2 (Microsoft Excel format). Data for correlating the unbound drug concentration in macaque plasma with the IC50 for pSer935-LRRK2 inhibition in mouse brain.
  • Data file S3 (Microsoft Excel format). Concentration of di-22:6-BMP in the urine of macaques.
  • Data file S4 (Microsoft Excel format). Lung function tests in macaques treated with MLi-2.
  • Data file S5 (Microsoft Excel format). Phosphatidylcholine in bronchoalveolar lavage from MLi-2–treated animals.
  • Data file S6 (Microsoft Excel format). Western blotting of pThr73 Rab10 in lung of GNE-7915–treated macaques.